PCVX:NSD-Vaxcyte Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 83.36

Change

+0.89 (+1.08)%

Market Cap

USD 10.11B

Volume

0.72M

Analyst Target

USD 49.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.57 (+1.82%)

USD 118.90B
ARGX argenx NV ADR

+7.35 (+1.15%)

USD 40.41B
ALNY Alnylam Pharmaceuticals Inc

+0.49 (+0.20%)

USD 34.99B
ONC BeiGene, Ltd.

+7.51 (+3.17%)

USD 25.62B
RPRX Royalty Pharma Plc

+0.74 (+2.27%)

USD 18.65B
SMMT Summit Therapeutics PLC

+1.46 (+6.76%)

USD 17.52B
UTHR United Therapeutics Corporatio..

-13.42 (-3.52%)

USD 15.68B
INCY Incyte Corporation

+1.22 (+1.74%)

USD 14.29B
INSM Insmed Inc

-0.22 (-0.26%)

USD 13.70B
MRNA Moderna Inc

-2.17 (-6.04%)

USD 12.93B

ETFs Containing PCVX

WELL:PA HAN-GINS Indxx Healthcare.. 6.32 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 6.32 % 0.00 %

N/A

N/A
HVAX:CA 4.86 % 0.00 %

N/A

N/A
MEDI Harbor Health Care ETF 4.57 % 0.00 %

-0.03 (-1.06%)

USD 0.02B
CURE:AU ETFS S&P Biotech ETF 2.28 % 0.00 %

+0.60 (+-1.06%)

USD 0.04B
VTWG Vanguard Russell 2000 Gro.. 0.76 % 0.20 %

-1.96 (-1.06%)

USD 1.05B
RSSL Global X Funds 0.39 % 0.00 %

-0.84 (-1.06%)

USD 1.55B
VTWO Vanguard Russell 2000 Ind.. 0.39 % 0.15 %

-0.86 (-1.06%)

USD 11.80B
ITWO Proshares Russell 2000 Hi.. 0.38 % 0.00 %

-0.43 (-1.06%)

USD 0.05B
XRS2:SW Xtrackers Russell 2000 UC.. 0.37 % 0.00 %

-6.60 (-1.06%)

USD 2.29B
R2US:SW SPDR® Russell 2000 US Sm.. 0.37 % 0.00 %

-1.02 (-1.06%)

USD 5.15B
UWM ProShares Ultra Russell20.. 0.32 % 0.95 %

-0.74 (-1.06%)

USD 0.43B
URTY ProShares UltraPro Russel.. 0.27 % 0.95 %

-1.49 (-1.06%)

USD 0.41B
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

-0.01 (-1.06%)

USD 0.02B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

-2.17 (-1.06%)

N/A
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

-2.86 (-1.06%)

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

-4.13 (-1.06%)

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

-3.17 (-1.06%)

USD 10.02B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.95 (-1.06%)

USD 5.13B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.83 (-1.06%)

USD 5.13B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-465.00 (-1.06%)

USD 2.29B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-4.39 (-1.06%)

USD 2.29B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-1.21 (-1.06%)

USD 5.14B
XRS2:F 0.00 % 0.00 %

N/A

N/A
ZPRR:F 0.00 % 0.00 %

N/A

N/A
XRS2:XETRA 0.00 % 0.00 %

N/A

N/A
ZPRR:XETRA 0.00 % 0.00 %

N/A

N/A
W311:XETRA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
W311:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.83% 62% D 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.83% 62% D 53% F
Trailing 12 Months  
Capital Gain 15.36% 76% C+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.36% 76% C+ 65% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 39.99% 75% C 84% B
Dividend Return 39.99% 75% C 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 54.24% 61% D- 36% F
Risk Adjusted Return 73.72% 98% N/A 88% B+
Market Capitalization 10.11B 98% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector